Virtual Bronchoscopy (VB) vs. Endobronchial Ultrasound (EBUS) Guided Mediastinal Sampling (VB/EBUS-TBNA)
Primary Purpose
Lung Cancer,, Mediastinal Tumors,, Lymphomas,
Status
Unknown status
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
virtual bronchoscopy guided transbronchial needle aspiration
endobronchial ultrasound guided transbronchial needle aspiration
Sponsored by
About this trial
This is an interventional diagnostic trial for Lung Cancer, focused on measuring EBUS guided transbronchial needle aspiration (EBUS-TBNA), virtual bronchoscopy (VB), VB guided transbronchial needle aspiration VB-TBNA), mediastinal sampling, transbronchial needle aspiration (TBNA)
Eligibility Criteria
Inclusion Criteria:
- provided informed consent
- mediastinal mass or lymph node enlargement that requires bronchoscopy and transbronchial sampling
- quality of the CT scan which allows bronchial tree and mediastinal target segmentation and reconstruction
Exclusion Criteria:
- Age below 18 years
- known contraindications for bronchoscopy and/or mediastinal sampling, e.g. coagulation disorders
Sites / Locations
- Department of Internal Medicine, Pneumonology and Allergology, Medical University of WarsawRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
virtual bronchoscopy guided transbronchial needle aspiration
Arm Description
virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA)(experimental method) and EBUS-TBNA (reference method) are performed in the same diagnostic session
Outcomes
Primary Outcome Measures
Adequacy of cytologic specimens collected by VB-TBNA vs. EBUS-TBNA
Comparison of the quality and adequacy of the cytologic specimens (in terms of lymphocyte percentage, the presence of neoplastic cells and dust-laden macrophages) collected by VB-TBNA vs. EBUS-TBNA in patients with mediastinal mass or mediastinal lymph node enlargement
Secondary Outcome Measures
Diagnostic accuracy of VB-TBNA vs. EBUS-TBNA - the number (and percentage) of cytologic specimens containing diagnostic material (neoplastic cells, granulomas)
Comparison of the diagnostic accuracy of VB-TBNA vs. EBUS-TBNA (in terms of number of cytologic specimens containing diagnostic material e.g. neoplastic cells, granulomas) in patients with mediastinal mass or mediastinal lymph node enlargement. Also the number of patients in whom the specific diagnosis could be established by VB-TBNA vs EBUS-TBNA.
Full Information
NCT ID
NCT01784185
First Posted
January 24, 2013
Last Updated
January 10, 2014
Sponsor
Medical University of Warsaw
Collaborators
Warsaw University of Technology
1. Study Identification
Unique Protocol Identification Number
NCT01784185
Brief Title
Virtual Bronchoscopy (VB) vs. Endobronchial Ultrasound (EBUS) Guided Mediastinal Sampling
Acronym
VB/EBUS-TBNA
Official Title
Development and Evaluation of Clinical Utility of Virtual Bronchoscopy (VB)-Based System for Bronchoscopic Navigation, Mediastinal Mapping and Transbronchial Aspiration of Mediastinal Lesions.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Unknown status
Study Start Date
January 2013 (undefined)
Primary Completion Date
February 2014 (Anticipated)
Study Completion Date
April 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Warsaw
Collaborators
Warsaw University of Technology
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study has been designed to evaluate the clinical application of the new virtual bronchoscopy (VB) -based system for transbronchial sampling of the mediastinal masses or enlarged lymph nodes. The software uses data from thorax CT scan and enables airway segmentation and reconstruction simultaneously with predefined mediastinal targets. The most suitable sites for transbronchial needle aspiration are displayed on the internal surface of the airways showed in VB mode.
The diagnostic yield of the new system-assisted TBNA will be compared to the reference method (EBUS-TBNA). The study group includes patients with mediastinal mass or lymph node enlargement in whom diagnostic bronchoscopy and TBNA can be applied as diagnostic methods. Both, virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA) and EBUS-TBNA of the mediastinal targets are performed during the same diagnostic bronchoscopy. Cytologic material from VB-TBNA and EBUS-TBNA is evaluated by two independent pathologists blinded to the method used to obtain the sample. Diagnostic yield and adequacy of aspirates obtained with the two methods will be assessed and compared.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer,, Mediastinal Tumors,, Lymphomas,, Sarcoidosis,
Keywords
EBUS guided transbronchial needle aspiration (EBUS-TBNA), virtual bronchoscopy (VB), VB guided transbronchial needle aspiration VB-TBNA), mediastinal sampling, transbronchial needle aspiration (TBNA)
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Investigator
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
virtual bronchoscopy guided transbronchial needle aspiration
Arm Type
Experimental
Arm Description
virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA)(experimental method) and EBUS-TBNA (reference method) are performed in the same diagnostic session
Intervention Type
Procedure
Intervention Name(s)
virtual bronchoscopy guided transbronchial needle aspiration
Other Intervention Name(s)
VB-TBNA
Intervention Type
Procedure
Intervention Name(s)
endobronchial ultrasound guided transbronchial needle aspiration
Other Intervention Name(s)
EBUS-TBNA
Intervention Description
endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
Primary Outcome Measure Information:
Title
Adequacy of cytologic specimens collected by VB-TBNA vs. EBUS-TBNA
Description
Comparison of the quality and adequacy of the cytologic specimens (in terms of lymphocyte percentage, the presence of neoplastic cells and dust-laden macrophages) collected by VB-TBNA vs. EBUS-TBNA in patients with mediastinal mass or mediastinal lymph node enlargement
Time Frame
Approximately five days after the procedure, when the results of the cytological examination will be available
Secondary Outcome Measure Information:
Title
Diagnostic accuracy of VB-TBNA vs. EBUS-TBNA - the number (and percentage) of cytologic specimens containing diagnostic material (neoplastic cells, granulomas)
Description
Comparison of the diagnostic accuracy of VB-TBNA vs. EBUS-TBNA (in terms of number of cytologic specimens containing diagnostic material e.g. neoplastic cells, granulomas) in patients with mediastinal mass or mediastinal lymph node enlargement. Also the number of patients in whom the specific diagnosis could be established by VB-TBNA vs EBUS-TBNA.
Time Frame
up to 8 months
Other Pre-specified Outcome Measures:
Title
Number of patients with local complications of VB-TBNA
Description
Number of patients in whom large mediastinal vessels would be injured when performing VB-TBNA will be compared with respective number of patients with EBUS-TBNA associated large vessel injury.
Time Frame
During VB-TBNA and EBUS-TBNA procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
provided informed consent
mediastinal mass or lymph node enlargement that requires bronchoscopy and transbronchial sampling
quality of the CT scan which allows bronchial tree and mediastinal target segmentation and reconstruction
Exclusion Criteria:
Age below 18 years
known contraindications for bronchoscopy and/or mediastinal sampling, e.g. coagulation disorders
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rafal Krenke, MD, PhD
Phone
+48225992562
Email
rafalkrenke@interia.pl
First Name & Middle Initial & Last Name or Official Title & Degree
Piotr Korczynski, MD, PhD
Phone
+48225992562
Email
drkorczynski@gmail.com
Facility Information:
Facility Name
Department of Internal Medicine, Pneumonology and Allergology, Medical University of Warsaw
City
Warsaw
ZIP/Postal Code
02-097
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rafal Krenke, MD, PhD
Phone
+48225992562
Email
rafalkrenke@interia.pl
First Name & Middle Initial & Last Name & Degree
Rafal Krenke, MD, PhD
First Name & Middle Initial & Last Name & Degree
Piotr Korczynski, MD, PhD
First Name & Middle Initial & Last Name & Degree
Renata Langfort, MD, PhD
First Name & Middle Initial & Last Name & Degree
Joanna Domagala-Kulawik, MD, PhD
12. IPD Sharing Statement
Learn more about this trial
Virtual Bronchoscopy (VB) vs. Endobronchial Ultrasound (EBUS) Guided Mediastinal Sampling
We'll reach out to this number within 24 hrs